AFFIMED NV (AFMD)
NL0015001ZQ0 - Common Stock
Overall AFMD gets a fundamental rating of 2 out of 10. We evaluated AFMD against 588 industry peers in the Biotechnology industry. AFMD may be in some trouble as it scores bad on both profitability and health. AFMD is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AFMD had negative earnings in the past year.
AFMD had a negative operating cash flow in the past year.
In the past 5 years AFMD always reported negative net income.
AFMD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -109.04%, AFMD is not doing good in the industry: 80.03% of the companies in the same industry are doing better.
AFMD has a Return On Equity of -183.27%. This is in the lower half of the industry: AFMD underperforms 69.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -109.04% | ||
| ROE | -183.27% | ||
| ROIC | N/A |
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.93%
ROE(5y)-84.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 83.70%, AFMD belongs to the top of the industry, outperforming 89.08% of the companies in the same industry.
AFMD's Gross Margin has declined in the last couple of years.
AFMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
2. Health
2.1 Basic Checks
AFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
AFMD has less shares outstanding than it did 1 year ago.
AFMD has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, AFMD has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.84, we must say that AFMD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.84, AFMD is in line with its industry, outperforming 55.29% of the companies in the same industry.
A Debt/Equity ratio of 0.22 indicates that AFMD is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.22, AFMD is not doing good in the industry: 68.09% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.84 |
ROIC/WACCN/A
WACC6.76%
2.3 Liquidity
A Current Ratio of 3.25 indicates that AFMD has no problem at all paying its short term obligations.
With a Current ratio value of 3.25, AFMD is not doing good in the industry: 63.99% of the companies in the same industry are doing better.
AFMD has a Quick Ratio of 3.23. This indicates that AFMD is financially healthy and has no problem in meeting its short term obligations.
AFMD has a worse Quick ratio (3.23) than 62.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.25 | ||
| Quick Ratio | 3.23 |
3. Growth
3.1 Past
The earnings per share for AFMD have decreased strongly by -1075.00% in the last year.
Looking at the last year, AFMD shows a very negative growth in Revenue. The Revenue has decreased by -79.99% in the last year.
The Revenue for AFMD have been decreasing by -19.01% on average. This is quite bad
EPS 1Y (TTM)-1075%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-513.64%
Revenue 1Y (TTM)-79.99%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19.01%
Revenue growth Q2Q-96.3%
3.2 Future
The Earnings Per Share is expected to grow by 14.40% on average over the next years. This is quite good.
Based on estimates for the next years, AFMD will show a very strong growth in Revenue. The Revenue will grow by 68.84% on average per year.
EPS Next Y29.38%
EPS Next 2Y22.03%
EPS Next 3Y16.67%
EPS Next 5Y14.4%
Revenue Next Year-44.65%
Revenue Next 2Y-19.68%
Revenue Next 3Y22.17%
Revenue Next 5Y68.84%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AFMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AFMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AFMD's earnings are expected to grow with 16.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.03%
EPS Next 3Y16.67%
5. Dividend
5.1 Amount
No dividends for AFMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AFFIMED NV
NASDAQ:AFMD (5/2/2024, 7:00:00 PM)
5.3
-0.03 (-0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap80.72M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -109.04% | ||
| ROE | -183.27% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.7% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.25 | ||
| Quick Ratio | 3.23 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1075%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y29.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-79.99%
Revenue growth 3Y-33.67%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y